Iza Bren Extends Progression Control After EGFR Therapy

Company SystImmune; Sichuan Biokin; Bristol Myers Squibb Event Type Phase 3 interim readout and publication Modality Bispecific EGFR/HER3 antibody-drug conjugate Asset Izalontamab brengitecan (iza-bren, BL-B01D1) Target EGFR; HER3 (topoisomerase-I payload) Disease Area EGFR-mutant NSCLC after EGFR TKI progression Summary The China Phase III PANKU-Lung01 trial…